Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Redosing CP-870,893 in Solid Tumors
NCT02157831Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2005
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selicrelumab in solid tumor, sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 8 weeks. Started Jul 2005; status: completed.
02
Drugs
selicrelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02157831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157831.